Verona Pharma plc Files Definitive Proxy Statement
| Field | Detail |
|---|---|
| Company | Verona Pharma PLC |
| Form Type | DEFA14A |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 12 |
| Reading Time | 14 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, human-resources
Related Tickers: VRNA
TL;DR
Verona Pharma plc filed its proxy statement, shareholders need to pay attention to upcoming votes.
AI Summary
Verona Pharma plc filed a Definitive Proxy Statement (DEFA14A) on September 10, 2025. The filing includes a message from Ostra Jewell, Senior Vice President of Human Resources, delivered via email. This document is related to the company's proxy solicitation efforts.
Why It Matters
This filing is a standard regulatory requirement for public companies, indicating that Verona Pharma plc is seeking shareholder votes or input on corporate matters.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently signal new risks.
Key Numbers
- 20250910 — Filing Date (The date the DEFA14A was filed with the SEC.)
Key Players & Entities
- Verona Pharma plc (company) — Registrant
- Ostra Jewell (person) — Senior Vice President, Human Resources
- 20549 (dollar_amount) — SEC Filing Zip Code
- 0001104659-25-089106 (dollar_amount) — Accession Number
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, also known as a Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting.
Who is Ostra Jewell and what is their role at Verona Pharma plc?
Ostra Jewell is the Senior Vice President of Human Resources at Verona Pharma plc, as indicated in the filing.
When was this filing made?
This filing was made on September 10, 2025.
What is the company's ticker symbol?
The ticker symbol is not explicitly mentioned in this excerpt, but the SEC file number is 001-38067.
What industry does Verona Pharma plc operate in?
Verona Pharma plc operates in the Pharmaceutical Preparations industry, with SIC code 2834.
Filing Stats: 3,605 words · 14 min read · ~12 pages · Grade level 15.3 · Accepted 2025-09-10 17:00:20
Filing Documents
- tm2525748d1_defa14a.htm (DEFA14A) — 55KB
- tm2525748d1_defa14aimg001.jpg (GRAPHIC) — 89KB
- tm2525748d1_defa14aimg002.jpg (GRAPHIC) — 280KB
- tm2525748d1_defa14aimg003.jpg (GRAPHIC) — 214KB
- tm2525748d1_defa14aimg004.jpg (GRAPHIC) — 234KB
- tm2525748d1_defa14aimg005.jpg (GRAPHIC) — 75KB
- tm2525748d1_defa14aimg006.jpg (GRAPHIC) — 36KB
- tm2525748d1_defa14aimg007.jpg (GRAPHIC) — 86KB
- tm2525748d1_defa14aimg008.jpg (GRAPHIC) — 92KB
- tm2525748d1_defa14aimg009.jpg (GRAPHIC) — 179KB
- tm2525748d1_defa14aimg010.jpg (GRAPHIC) — 147KB
- tm2525748d1_defa14aimg011.jpg (GRAPHIC) — 162KB
- tm2525748d1_defa14aimg012.jpg (GRAPHIC) — 188KB
- tm2525748d1_defa14aimg013.jpg (GRAPHIC) — 161KB
- tm2525748d1_defa14aimg014.jpg (GRAPHIC) — 41KB
- tm2525748d1_defa14aimg015.jpg (GRAPHIC) — 202KB
- tm2525748d1_defa14aimg016.jpg (GRAPHIC) — 79KB
- tm2525748d1_defa14aimg017.jpg (GRAPHIC) — 17KB
- 0001104659-25-089106.txt ( ) — 3176KB
Forward-Looking Statements
Forward-Looking Statements This communication includes “forward-looking with respect to the proposed acquisition of Verona Pharma, and readers are cautioned not to place undue reliance on such statements. Such forward-looking statements include, but are not limited to, the ability of Merck and Verona Pharma to complete the transactions contemplated by the transaction agreement, including statements about the transaction contemplated thereby, statements about the expected timetable for completing the transaction, Verona Pharma’s beliefs and expectations and statements about the benefits sought to be achieved in the proposed acquisition, the potential effects of the acquisition on Verona Pharma, as well as the expected benefits and success of Verona Pharma’s products and product candidates. These statements are based upon the current beliefs and expectations of Verona Pharma’s management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable or at all, or that any pipeline candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the proposed transaction; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the proposed transaction contained in the transaction agreement may not be satisfied or waived (including, but not limited to, the failure to obtain the approval of the propo